Compared to premenopausal women, perimenopausal and postmenopausal women exhibited brain hypometabolism on 18F-fluorodeoxyglucose positron-emission tomography in the same brain regions as do patients with clinical AD. The findings correlated with reductions in mitochondrial cytochrome oxidase (COX) activity. {read more here}
Known as 68Ga-THP-PSMA, the new tracer, which was developed with support from the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, can be made very quickly and easily in a radio-pharmacy, meaning that smaller hospitals and clinics can produce it. It is hoped that this will mean more patients will have access to high-quality lifesaving scans. {read more here}
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational clinical trial evaluating the impact of fluciclovine (18F) PET/CT imaging on clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy. {read more here}
Researchers in Norway have shown the superiority of combined fluciclovine F-18 PET with multiparametric MRI over either modality alone for detecting and characterizing high-risk prostate cancers, according to a study published Oct. 6 in the Journal of Nuclear Medicine. {read more here}